Acurx Pharmaceuticals Inc
ACXP3.330USD
-0.120-3.48%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
5.99MMarket Cap
LossP/E TTM
More Details of Acurx Pharmaceuticals Inc Company
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
Acurx Pharmaceuticals Inc Info
Ticker SymbolACXP
Company nameAcurx Pharmaceuticals Inc
IPO dateJun 25, 2021
CEOLuci (David P)
Number of employees4
Security typeOrdinary Share
Fiscal year-endJun 25
Address259 Liberty Avenue
CitySTATEN ISLAND
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10305
Phone19175331469
Websitehttps://www.acurxpharma.com/
Ticker SymbolACXP
IPO dateJun 25, 2021
CEOLuci (David P)
Company Executives of Acurx Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David P. Luci
Mr. David P. Luci
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
57.38K
--
Mr. Robert J. Deluccia
Mr. Robert J. Deluccia
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
50.70K
--
Mr. Robert G. Shawah, CPA
Mr. Robert G. Shawah, CPA
Co-Founder, Chief Financial Officer
Co-Founder, Chief Financial Officer
9.46K
--
Mr. Joseph C. Scodari
Mr. Joseph C. Scodari
Independent Director
Independent Director
1.39K
--
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
77.00
--
Mr. Carl V. Sailer
Mr. Carl V. Sailer
Independent Director
Independent Director
--
--
Dr. Jack Hugh Dean, Ph.D.
Dr. Jack Hugh Dean, Ph.D.
Independent Director
Independent Director
--
--
Mr. James J. Donohue
Mr. James J. Donohue
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. David P. Luci
Mr. David P. Luci
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
57.38K
--
Mr. Robert J. Deluccia
Mr. Robert J. Deluccia
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
50.70K
--
Mr. Robert G. Shawah, CPA
Mr. Robert G. Shawah, CPA
Co-Founder, Chief Financial Officer
Co-Founder, Chief Financial Officer
9.46K
--
Mr. Joseph C. Scodari
Mr. Joseph C. Scodari
Independent Director
Independent Director
1.39K
--
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
77.00
--
Mr. Carl V. Sailer
Mr. Carl V. Sailer
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Luci (David P)
2.75%
DeLuccia (Robert J)
2.43%
Prospect Financial Services LLC
0.95%
Susquehanna International Group, LLP
0.81%
Shawah (Robert G)
0.45%
Other
92.60%
Shareholders
Shareholders
Proportion
Luci (David P)
2.75%
DeLuccia (Robert J)
2.43%
Prospect Financial Services LLC
0.95%
Susquehanna International Group, LLP
0.81%
Shawah (Robert G)
0.45%
Other
92.60%
Shareholder Types
Shareholders
Proportion
Individual Investor
6.17%
Investment Advisor
2.53%
Investment Advisor/Hedge Fund
0.42%
Hedge Fund
0.05%
Research Firm
0.04%
Other
90.79%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
52
63.38K
10.97%
--
2025Q3
54
63.38K
14.50%
-157.72K
2025Q2
54
130.55K
15.66%
-44.44K
2025Q1
51
175.00K
9.31%
+70.72K
2024Q4
49
71.81K
12.40%
+8.43K
2024Q3
46
63.38K
12.66%
+2.99K
2024Q2
46
60.39K
13.22%
-2.22K
2024Q1
45
62.60K
12.36%
-34.79K
2023Q4
42
54.80K
8.44%
+10.64K
2023Q3
33
44.19K
14.01%
-30.63K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Luci (David P)
57.38K
3.62%
--
--
Aug 05, 2025
DeLuccia (Robert J)
50.70K
3.2%
--
--
Aug 05, 2025
Prospect Financial Services LLC
14.84K
0.94%
-3.49K
-19.04%
Jun 30, 2025
Susquehanna International Group, LLP
3.49K
0.22%
+3.49K
--
Jun 30, 2025
Shawah (Robert G)
9.46K
0.6%
--
--
Aug 05, 2025
Sabby Management, LLC
4.09K
0.26%
-98.13K
-95.99%
Jun 30, 2025
Sailer (Carl)
7.11K
0.45%
--
--
Aug 05, 2025
Morgan Stanley Smith Barney LLC
5.31K
0.34%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 31, 2025
Merger
20→1
Date
Type
Ratio
Jul 31, 2025
Merger
20→1
FAQs
Who are the top five shareholders of Acurx Pharmaceuticals Inc?
The top five shareholders of Acurx Pharmaceuticals Inc are:
Luci (David P) holds 57.38K shares, accounting for 3.62% of the total shares.
DeLuccia (Robert J) holds 50.70K shares, accounting for 3.20% of the total shares.
Prospect Financial Services LLC holds 14.84K shares, accounting for 0.94% of the total shares.
Susquehanna International Group, LLP holds 3.49K shares, accounting for 0.22% of the total shares.
Shawah (Robert G) holds 9.46K shares, accounting for 0.60% of the total shares.
Luci (David P) holds 57.38K shares, accounting for 3.62% of the total shares.
DeLuccia (Robert J) holds 50.70K shares, accounting for 3.20% of the total shares.
Prospect Financial Services LLC holds 14.84K shares, accounting for 0.94% of the total shares.
Susquehanna International Group, LLP holds 3.49K shares, accounting for 0.22% of the total shares.
Shawah (Robert G) holds 9.46K shares, accounting for 0.60% of the total shares.
What are the top three shareholder types of Acurx Pharmaceuticals Inc?
The top three shareholder types of Acurx Pharmaceuticals Inc are:
Luci (David P)
DeLuccia (Robert J)
Prospect Financial Services LLC
Luci (David P)
DeLuccia (Robert J)
Prospect Financial Services LLC
How many institutions hold shares of Acurx Pharmaceuticals Inc (ACXP)?
As of 2025Q4, 52 institutions hold shares of Acurx Pharmaceuticals Inc, with a combined market value of approximately 63.38K, accounting for 10.97% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.53%.
What is the biggest source of revenue for Acurx Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Acurx Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
